Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy
Michael Kulis, Katie Saba, Edwin H Kim, J Andrew Bird, Nikolas Kamilaris, Brian P Vickery, Herman Staats, A Wesley Burks, Michael Kulis, Katie Saba, Edwin H Kim, J Andrew Bird, Nikolas Kamilaris, Brian P Vickery, Herman Staats, A Wesley Burks
Abstract
Capsule Summary: Peanut-specific IgA in saliva correlates with DBPCFC outcomes following peanut SLIT, suggesting that peanut-specific salivary IgA may be a potential biomarker for SLIT used to treat peanut allergy.
Figures
Peanut-specific IgA in saliva and serum. A, C, and E show individual data with a line indicating the median for salivary peanut-IgA, salivary peanut-secretory IgA, and serum peanut-IgA, respectively. B, D, and F show changes for individuals from 0 mo to 12 mo for salivary peanut-IgA, salivary peanut-secretory IgA, and serum peanut-IgA, respectively. Matched pairs were compared by Wilcoxon Signed-Rank Test; SLIT and placebo were compared with the Mann-Whitney Test.
Correlations of DBPCFC or baseline peanut-IgE with changes in peanut-IgA. A: Salivary peanut-IgA, B: Salivary peanut-secretory-IgA, and C: serum peanut-IgA plotted with mg of peanut protein consumed during DBPCFC. Linear regression analysis was used to determine if best-fit line slopes were significantly non-zero. D: Scatter plot of baseline peanut-IgE and change in salivary peanut-IgA.Blue circles represent SLIT subjects; Red diamonds represent placebo subjects.
Source: PubMed